NASDAQ:VINC Vincerx Pharma (VINC) Stock Price, News & Analysis $0.04 -0.01 (-18.78%) As of 08/8/2025 03:45 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vincerx Pharma Stock (NASDAQ:VINC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vincerx Pharma alerts:Sign Up Key Stats Today's Range$0.03▼$0.0550-Day Range$0.03▼$0.0652-Week Range$0.03▼$17.00Volume183,586 shsAverage Volume603,834 shsMarket Capitalization$208.31 thousandP/E RatioN/ADividend YieldN/APrice Target$40.00Consensus RatingBuy Company Overview Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California. Read More Vincerx Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreVINC MarketRank™: Vincerx Pharma scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVincerx Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVincerx Pharma has received no research coverage in the past 90 days.Read more about Vincerx Pharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vincerx Pharma are expected to grow in the coming year, from ($10.00) to ($6.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vincerx Pharma is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vincerx Pharma is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVincerx Pharma has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vincerx Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the outstanding shares of Vincerx Pharma have been sold short.Short Interest Ratio / Days to CoverVincerx Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVincerx Pharma does not currently pay a dividend.Dividend GrowthVincerx Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.02% of the outstanding shares of Vincerx Pharma have been sold short.Short Interest Ratio / Days to CoverVincerx Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media1.1 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Vincerx Pharma this week, compared to 1 article on an average week.Search Interest8 people have searched for VINC on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows3 people have added Vincerx Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vincerx Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders15.60% of the stock of Vincerx Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.02% of the stock of Vincerx Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vincerx Pharma's insider trading history. Receive VINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address VINC Stock News HeadlinesVincerx Pharma (NASDAQ:VINC) vs. NovaBay Pharmaceuticals (NYSE:NBY) Head to Head SurveyAugust 8 at 2:51 AM | americanbankingnews.comVincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...July 16, 2025 | gurufocus.comHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation. | Paradigm Press (Ad)Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution ProposalJuly 16, 2025 | globenewswire.comVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - MorningstarJuly 9, 2025 | morningstar.comMVincerx Pharma, Inc. Common Stock (VINC) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to StockholdersJuly 7, 2025 | globenewswire.comVincerx Pharma, Inc. (VINC) - Yahoo FinanceJuly 2, 2025 | ca.finance.yahoo.comSee More Headlines VINC Stock Analysis - Frequently Asked Questions How have VINC shares performed this year? Vincerx Pharma's stock was trading at $5.2560 at the beginning of 2025. Since then, VINC shares have decreased by 99.2% and is now trading at $0.0398. How were Vincerx Pharma's earnings last quarter? Vincerx Pharma, Inc. (NASDAQ:VINC) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($1.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.40) by $2.40. When did Vincerx Pharma's stock split? Shares of Vincerx Pharma reverse split before market open on Tuesday, January 28th 2025.The 1-20 reverse split was announced on Thursday, January 23rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Vincerx Pharma? Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vincerx Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vincerx Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and CymaBay Therapeutics (CBAY). Company Calendar Last Earnings8/08/2024Today8/09/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VINC CIK1796129 Webvincerapharma.com Phone650-800-6676FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Vincerx Pharma$40.00 High Price Target$40.00 Low Price Target$40.00 Potential Upside/Downside+100,402.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($20.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$40.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-248.33% Return on Assets-132.73% Debt Debt-to-Equity RatioN/A Current Ratio2.17 Quick Ratio2.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.50 per share Price / Book0.00Miscellaneous Outstanding Shares5,234,000Free Float1,891,000Market Cap$208.31 thousand OptionableNot Optionable Beta1.71 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:VINC) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vincerx Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.